Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8,900 JPY | -2.31% | -19.89% | +24.82% |
Mar. 25 | Towa Pharmaceutical Completes Payment for Director Stock Compensation | MT |
Feb. 07 | Towa Corporation Provides Dividend Guidance for the Year Ending March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With an expected P/E ratio at 39.08 and 25.64 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.57 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Semiconductor Equipment & Testing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.82% | 1.47B | - | ||
+20.97% | 163B | A- | ||
+34.59% | 33.84B | C- | ||
+25.55% | 31.03B | B+ | ||
-21.93% | 26.17B | - | ||
+24.13% | 22.32B | C | ||
+1.87% | 11.44B | B+ | ||
+131.12% | 10B | - | ||
+28.55% | 6.2B | - | - | |
-21.78% | 4.91B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6315 Stock
- Ratings TOWA Corporation